Free Trial
NASDAQ:MNMD

Mind Medicine (MindMed) Q2 2025 Earnings Report

Mind Medicine (MindMed) logo
$9.76 +0.04 (+0.41%)
Closing price 07/25/2025 04:00 PM Eastern
Extended Trading
$9.68 -0.08 (-0.82%)
As of 07/25/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mind Medicine (MindMed) EPS Results

Actual EPS
N/A
Consensus EPS
-$0.37
Beat/Miss
N/A
One Year Ago EPS
N/A

Mind Medicine (MindMed) Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Mind Medicine (MindMed) Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Thursday, July 31, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Mind Medicine (MindMed) Earnings Headlines

Mind Medicine: Heading In The Right Direction
I warned you about Nvidia… now look what’s happening
Nvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before the open. That’s the kind of move Tim Sykes built his XGPT system to trade. It scans AI news in real time, filters the noise, and pinpoints when to strike. He’s now showing exactly how it works — before the next headline hits.
MindMed Announces New Employee Inducement Grants
MNMD Mind Medicine (MindMed) Inc. - Seeking Alpha
See More Mind Medicine (MindMed) Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Mind Medicine (MindMed)? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Mind Medicine (MindMed) and other key companies, straight to your email.

About Mind Medicine (MindMed)

Mind Medicine (MindMed) (NASDAQ:MNMD), a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

View Mind Medicine (MindMed) Profile

More Earnings Resources from MarketBeat